Application of PLX3397 in treatment of colorectal cancer

Abstract

The invention belongs to the technical field of medicines, particularly relates to application of PLX3397 in treatment of colorectal cancer, and discloses novel application of PLX3397, namely application of PLX3397 in treatment of colorectal cancer. Research finds that oral administration of PLX3397 can significantly inhibit malignant proliferation of subcutaneous transplanted tumor of colorectal cancer, and also can significantly reduce liver metastasis of colorectal cancer, and the combination of PLX3397 and 5-FU can achieve a combined synergistic effect. The PLX3397 can be prepared into the medicine for treating the colorectal cancer, or the medicine for inhibiting the proliferation of the colorectal cancer cells, or the medicine for reducing the liver metastasis of the colorectal cancer cells. Meanwhile, the PLX3397 has low toxic and side effects when being used for treating the colorectal cancer, so that a new way and a new direction are provided for treatment of the colorectal cancer, and the PLX3397 has important application value.

Description

technical field [0001] The invention belongs to the technical field of medicine, in particular to the use of PLX3397 in the treatment of colorectal cancer. Background technique [0002] Colorectal cancer (CRC) is one of the most common malignant tumors, with the third highest incidence among all malignant tumors. Due to the low popularity of early screening such as colonoscopy, more than 35% of the patients have developed distant metastasis at the initial diagnosis and lost the chance of radical resection. They can only choose systemic systemic therapy to prolong their survival. Among them, chemotherapy is one of the standard treatment regimens for metastatic colorectal cancer (metastatic CRC, mCRC). The commonly used chemotherapy regimens are mainly 5-fluorouracil (5-FU), oxaliplatin or irinotecan. However, due to the high toxicity and intolerance of this regimen, it is difficult to break through the overall survival of chemotherapy. [0003] PD1 / PD-L1 immunotherapy has b...

AI Technical Summary

Problems solved by technology

(2) TAMs in the tumor microenvironment of CRC can also make tumor cells less sensitive to chemotherapeutic drugs

[0006] The first CSF1R-targeting inhibitor pexidartinib ((PLX3397, trade name: Turalio)) developed by the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd. has been approved by the US FDA in 2019 as a specific drug for tenosynovial giant cell tumor ( Tenosynovial giant cell tumor (TGCT) has good curative effect and low side effects, but there is no report on the application of this drug in the treatment of mCRC.

Images